Piper Sandler and Morgan Stanley Highlight Amgen (AMGN) on Pipeline Strength and

Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy right now. On June 12, Piper Sandler reaffirmed its Overweight rating and $427 price target for Amgen Inc. (NASDAQ:AMGN). The firm published a detailed review of the Sjogren's syndrome therapeutic development environment in advance of Amgen's CD40 ligand-directed fusion protein dazodalibep's Phase III conclusion in the latter half of 2026.

Amgen Inc. (NASDAQ:AMGN) is conducting research in two distinct Sjogren's categories: moderate-to-severe symptoms-related burden with low systemic disease progression and moderate-to-severe systemic disease activity.

According to Piper Sandler, dazodalibep is a comparatively underappreciated part of Amgen's growing immunology/inflammation pharmaceutical line.

In a similar vein, Morgan Stanley maintained its Overweight rating on Amgen Inc. (NASDAQ:AMGN) while increasing its price objective to $340 from $332 on June 9. The firm pointed out that Amgen's portfolio of cutting-edge medications is bolstered by the company's recent acquisition of Horizon.

According to Morgan Stanley, the stock's future depends on pipeline development, with a major focus on MariTide again

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/piper-sandler-morgan-stanley-highlight-111109075.html)